{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:12:27Z","timestamp":1791058347461,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ucl.2012.07.008","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T20:16:32Z","timestamp":1346444192000},"page":"517-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Yohann","family":"Loriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Zoubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2012.07.008_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdp530","article-title":"Cancer mortality in Europe, 2000\u20132004, and an overview of trends since 1975","volume":"21","author":"La Vecchia","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib2","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ucl.2012.07.008_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMra021562","article-title":"Prostate cancer","volume":"349","author":"Nelson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.008_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/sj.bjc.6603223","article-title":"Improving the outcome of patients with castration-resistant prostate cancer through rational drug development","volume":"95","author":"Attard","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","article-title":"Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target","volume":"10","author":"Chen","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib6","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2012.07.008_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ucl.2012.07.008_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib10","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib11","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.008_bib13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.008_bib14","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2010.34.3996","article-title":"Chemotherapy-based treatment for castration-resistant prostate cancer","volume":"29","author":"Seruga","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1535-7163.MCT-11-0289","article-title":"Identification of docetaxel resistance genes in castration-resistant prostate cancer","volume":"11","author":"Mar\u00edn-Aguilera","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2012.07.008_bib16","first-page":"2944","article-title":"Molecular determinants of docetaxel-resistance in prostate cancer cells","volume":"2009","author":"Al Nakouzi","year":"2009","journal-title":"AACR Meeting Abstracts"},{"key":"10.1016\/j.ucl.2012.07.008_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR\u00a0116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A\u00a0multicenter phase II study of XRP6258 administered as a 1-h I.V. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2012.07.008_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ncponc1281","article-title":"Epothilones: tubulin polymerization as a novel target for prostate cancer therapy","volume":"6","author":"Lee","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib21","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2012.07.008_bib22","first-page":"M79","article-title":"Epothilones and related structures\u2013a new class of microtubule inhibitors with potent in\u00a0vivo antitumor activity","volume":"1470","author":"Altmann","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ucl.2012.07.008_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/pros.20289","article-title":"Patupilone (epothilone B, EPO906) inhibits growth and\u00a0metastasis of experimental prostate tumors in\u00a0vivo","volume":"65","author":"O'Reilly","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2012.07.008_bib24","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1158\/0008-5472.CAN-05-1014","article-title":"Therapeutic cure against human tumor xenografts in nude mice by\u00a0a microtubule stabilization agent, fludelone, via parenteral or oral route","volume":"65","author":"Chou","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3816\/CBC.2007.n.009","article-title":"Efficacy and safety of ixabepilone, a novel epothilone analogue","volume":"7","author":"Pivot","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib26","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-08-0237","article-title":"Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone","volume":"68","author":"Hoffmann","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1200\/JCO.2005.09.042","article-title":"Multi-national randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer","volume":"23","author":"Galsky","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib28","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1200\/JCO.2005.02.4448","article-title":"Ixabepilone (epothilone B analogue BMS-247550) is active in\u00a0chemotherapy-na\u00efve patients with hormone-refractory prostate cancer: a Southwest Oncology Group Trial S0111","volume":"23","author":"Hussain","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib29","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2008.19.8002","article-title":"Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium","volume":"27","author":"Rosenberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity\u00a0of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib31","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/cncr.25810","article-title":"Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/annonc\/mdr336","article-title":"A\u00a0phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a","volume":"23","author":"Chi","year":"2012","journal-title":"Ann Oncol"},{"issue":"May 20 Suppl","key":"10.1016\/j.ucl.2012.07.008_bib33","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1200\/jco.2008.26.15_suppl.5141","article-title":"Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC)","volume":"26","author":"Graff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2012.07.008_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the\u00a0DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2012.07.008_bib36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.008_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1078-0432.CCR-09-2204","article-title":"MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer","volume":"16","author":"Kamal","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib40","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br\u00a0J Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1464-410X.2007.07331.x","article-title":"Response to docetaxel\/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer","volume":"101","author":"Nakabayashi","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2012.07.008_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.23195","article-title":"A\u00a0phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib44","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/annonc\/mdn694","article-title":"Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate\u00a0cancer: a prospective study evaluating also neuroendocrine features","volume":"20","author":"Loriot","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1464-410X.2011.10292.x","article-title":"Germline BRCA mutation does not prevent response to\u00a0taxane-based therapy for the treatment of castration-resistant prostate cancer","volume":"109","author":"Gallagher","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2012.07.008_bib47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ucl.2012.07.008_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.ucl.2012.07.008_bib49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.613","article-title":"Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements","volume":"42","author":"Haffner","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ucl.2012.07.008_bib50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ucl.2012.07.008_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.008_bib52","article-title":"Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"30","author":"Hussain","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib53","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1038\/sj.onc.1209598","article-title":"Mitochondria as therapeutic targets for cancer chemotherapy","volume":"25","author":"Galluzzi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2012.07.008_bib54","first-page":"6940","article-title":"Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer","volume":"52","author":"McDonnell","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib55","first-page":"404","article-title":"Technology evaluation: G-3139","volume":"1","author":"Banerjee","year":"1999","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.ucl.2012.07.008_bib56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1124\/mol.60.6.1296","article-title":"Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells","volume":"60","author":"Benimetskaya","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ucl.2012.07.008_bib57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ucl.2012.07.008_bib58","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1541-7786.MCR-09-0166","article-title":"Bcl-2 modulation to activate apoptosis in prostate cancer","volume":"7","author":"Bray","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib59","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-03-0701","article-title":"A\u00a0phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer","volume":"10","author":"Tolcher","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib60","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","article-title":"Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer","volume":"20","author":"Sternberg","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib61","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-08-2985","article-title":"An open-label, multicenter, phase I\/II study of single-agent AT-101 in men with castrate-resistant prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib62","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","article-title":"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer","volume":"23","author":"Sonpavde","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib63","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1158\/0008-5472.CAN-03-3998","article-title":"Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer","volume":"64","author":"Rocchi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib64","first-page":"170","article-title":"Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer","volume":"60","author":"Miyake","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1020172424152","article-title":"Antisense therapy: current status in prostate cancer and other malignancies","volume":"21","author":"Gleave","year":"2002","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ucl.2012.07.008_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/sj.neo.7900174","article-title":"Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin","volume":"3","author":"Zellweger","year":"2001","journal-title":"Neoplasia"},{"key":"10.1016\/j.ucl.2012.07.008_bib67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/15216540310001640498","article-title":"Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?","volume":"55","author":"Carver","year":"2003","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ucl.2012.07.008_bib68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-0854.2007.00549.x","article-title":"Stress-induced retrotranslocation of clusterin\/ApoJ into the cytosol","volume":"8","author":"Nizard","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.ucl.2012.07.008_bib69","first-page":"1707","article-title":"Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer","volume":"3","author":"Steinberg","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pros.10047","article-title":"Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy","volume":"50","author":"July","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2012.07.008_bib71","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/onc.2009.181","article-title":"Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis","volume":"28","author":"Song","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2012.07.008_bib72","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1464-410X.2008.07618.x","article-title":"Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy","volume":"102","author":"Sowery","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2012.07.008_bib73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00345-004-0474-0","article-title":"Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer","volume":"23","author":"Gleave","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2012.07.008_bib74","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A\u00a0phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2032-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2012.07.008_bib75","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-07-1310","article-title":"A\u00a0phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer","volume":"14","author":"Chi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib76","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib77","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.26.8771","article-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Chi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib78","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-11-0859","article-title":"Randomized phase II trial\u00a0of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","volume":"17","author":"Saad","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib79","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1158\/0008-5472.CAN-07-2057","article-title":"Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity","volume":"67","author":"Zoubeidi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib80","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1158\/0008-5472.CAN-09-3252","article-title":"Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD","volume":"70","author":"Zoubeidi","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib81","first-page":"887","article-title":"Role of HSP27 in tumor necrosis factor-\u03b1-stimulated interleukin-6 synthesis in osteoblasts","volume":"28","author":"Kato","year":"2011","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ucl.2012.07.008_bib82","first-page":"7099","article-title":"Heat shock protein expression independently predicts clinical outcome in prostate cancer","volume":"60","author":"Cornford","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib83","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1464-410X.2006.06425.x","article-title":"Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in\u00a0vitro","volume":"98","author":"Rocchi","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2012.07.008_bib84","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/onc.2009.479","article-title":"Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E","volume":"29","author":"Andrieu","year":"2010","journal-title":"Oncogene"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.008_bib85","first-page":"15s","article-title":"Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): final results","volume":"28","author":"Hotte","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.008_bib86","article-title":"A\u00a0randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"30","author":"Chi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib87","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.ejca.2010.02.028","article-title":"Targeting the HGF\/Met signalling pathway in cancer","volume":"46","author":"Cecchi","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pros.20068","article-title":"Targeting the HGF\/SF receptor c-met using a hammerhead ribozyme transgene reduces in\u00a0vitro invasion and migration in prostate cancer cells","volume":"60","author":"Davies","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2012.07.008_bib89","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.CAN-06-3552","article-title":"The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression","volume":"67","author":"Verras","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib90","first-page":"386","article-title":"Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma","volume":"147","author":"Humphrey","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ucl.2012.07.008_bib91","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/1078-0432.CCR-07-5110","article-title":"Predictive value of plasma hepatocyte growth factor\/scatter factor levels in patients with clinically localized prostate cancer","volume":"14","author":"Gupta","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib92","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pros.20890","article-title":"Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer","volume":"69","author":"Yasuda","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2012.07.008_bib93","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1158\/1535-7163.MCT-10-0359","article-title":"BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in\u00a0vitro","volume":"9","author":"Dai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2012.07.008_bib94","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2012.07.008_bib95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/1471-2407-10-556","article-title":"Efficacy of c-Met inhibitor for advanced prostate cancer","volume":"10","author":"Tu","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ucl.2012.07.008_bib96","doi-asserted-by":"crossref","unstructured":"Salgia R, Hong S, Sherman S, et\u00a0al. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with\u00a0advanced malignancies. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, October 22\u201326, 2007, A152.","DOI":"10.1200\/jco.2007.25.18_suppl.14031"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.008_bib97","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib98","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2010.34.4994","article-title":"Emerging therapies to prevent skeletal morbidity in men with prostate cancer","volume":"29","author":"Saylor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib99","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1038\/sj.onc.1211016","article-title":"Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells","volume":"27","author":"Asim","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2012.07.008_bib100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/0008-5472.CAN-10-1605","article-title":"Invasive prostate carcinoma driven by c-Src and androgen receptor synergy","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.008_bib101","article-title":"MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report","volume":"29","author":"Efstathiou","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib102","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10585-011-9436-2","article-title":"Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells","volume":"29","author":"Rice","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ucl.2012.07.008_bib103","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1073\/pnas.1103904108","article-title":"Differential transformation capacity of Src family kinases during the initiation of prostate cancer","volume":"108","author":"Cai","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ucl.2012.07.008_bib104","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ucl.2012.07.008_bib105","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/1078-0432.CCR-08-1857","article-title":"SRC family kinase activity is up-regulated in hormone-refractory prostate cancer","volume":"15","author":"Tatarov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib106","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","article-title":"Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib107","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjc.6605178","article-title":"Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model","volume":"101","author":"Koreckij","year":"2009","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.008_bib108","article-title":"Effect of dual inhibition of the Src and insulin-like growth factor-1 receptor (IGF-1R) pathways on antitumor effects in prostate cancer (PCa)","volume":"29","author":"Dayyani","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib109","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ucl.2012.07.008_bib110","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"de Vries","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib111","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-09-1058","article-title":"Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model","volume":"9","author":"Yang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2012.07.008_bib112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/0008-5472.CAN-08-0442","article-title":"Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib113","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1038\/onc.2008.250","article-title":"Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530","volume":"27","author":"Chang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2012.07.008_bib114","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.008_bib115","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2012.07.008_bib116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.008_bib117","article-title":"A\u00a0phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy","volume":"29","author":"Twardowski","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.008_bib118","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:24:51Z","timestamp":1758806691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014312000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0094014312000560"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.008","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}